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Background: Phytostanols are naturally occurring compounds©that reduce blood cholesterol
levels significantly. However, their aqueous insolubility poses formulation challenges.
Aim: To formulate and characterize solid lipid nanoparticle carriers for phytostanol esters to
enhance the bioavailability of phytostanols.
10Methods: Phytostanol ester solid lipid nanoparticles were formulated by the microemulsion
method. They were characterized for particle size distribution, polydispersity index, shape,
surface charge, entrapment efficiency, stability, chemical structure, and thermal properties.
The uptake of the formulation by cell lines, HepG2 and HT-29, and its effect on cell viability
were evaluated.
15Results: The formulation of solid lipid nanoparticles was successfully optimised by varying
the type of lipids and their concentration relative to that of surfactants in the present study.
The optimised formulation had an average diameter of (171 ± 9) nm, a negative surface
charge of (−23.0 ± 0.8) mV and©was generally spherical in shape. We report high levels of
drug entrapment at (89 ± 5)% in amorphous form, drug loading of (9.1 ± 0.5)%, nanoparticle
20yield of (67 ± 4)% and drug excipient compatibility. The biological safety and uptake of the
formulations were demonstrated on hepatic and intestinal cell lines.
Conclusion: Phytostanol ester solid lipid nanoparticles were successfully formulated and
characterized. The formulation has the potential to provide an innovative drug delivery
system for phytostanols which reduce cholesterol and have a potentially ideal safety profile.
25This can contribute to better management of one of the main risk factors of cardiovascular
diseases.
Keywords: cardiovascular diseases, cholesterol, phytostanol ester©PSEsolid lipid
nanoparticles©SLNPshypercholesterolemia
Introduction
Cardiovascular diseases are the leading cause of mortality accounting for approxi-
30mately 31% of annual global deaths (17.9 million people) in 2016.1 High total
cholesterol and low-density lipoprotein cholesterol (LDL-C) are modifiable risk
factors.2 LDL-C plays a major role in the progression of atherosclerosis, and an
elevated level of cholesterol was responsible for circa 4.5% of total deaths
(2.6 million lives) in 2004.3,4 Lowering of LDL-C levels significantly reduces
35cardiovascular morbidity and mortality risks.3 These risk factors are typically
treated with standard hypolipidemic agents, including statins, fibrates, bile acid-
binding resins and cholesterol absorption inhibitors.5 However, these agents are
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typically associated with various adverse drug reactions
such as muscle diseases, elevated activity of liver enzymes
40 and gastrointestinal symptoms.6–8 In addition to adverse
reactions, statin intolerance remains a therapeutic chal-
lenge, together with familial disorders, treatment resis-
tance, non-compliance and optimization of lipid-lowering
therapy especially in severe hypercholesterolemia.9,10
45 Hence, there is a need for novel, effective and safe ther-
apeutic compounds©that lower cholesterol without the
adverse effects of the current lipid-lowering agents.
Phytosterols (plant sterols) and phytostanols (plant sta-
nols) are naturally occurring substances©that are found in
50 variable amounts in fruits, vegetables, cereals, nuts, seeds,
etc.11,12 Phytosterols and phytostanols were chemically
identified in the 1920s by Anderson and Shriner.13,14
Subsequently, they were shown to have cholesterol-
lowering potential in experimental animals and humans
55 in the 1950s.15–18 Phytostanols are saturated derivatives
of sterols, saturated at C5-6 without double bonds.19
Stanols block both dietary and biliary intestinal cholesterol
absorption by competing with cholesterol for its access to
receptors and increasing its excretion. The efficacy and
60 safety of plant stanols have been demonstrated in
a multitude of well-designed and rigorously conducted
clinical studies.20–23 It has been shown that a daily intake
of 2–3 grams of plant stanols reduces LDL-C levels by
10–15% without side effects.19 There is also some evi-
65 dence that it reduces triglycerides.24–26
However, plant stanols are insoluble in water and con-
sequently have low bioavailability.27,28 The aqueous inso-
lubility poses a challenging problem during the
formulation of stanol products.29,30 Esterified forms of
70 phytostanols with improved fat solubility are currently
available in the market through various delivery vehicles
such as margarine, yogurt, vegetable spread, cereal bar,
soy products, chocolate, biscuit©.
23,31 These fortified foods
add to the daily caloric intake requiring isocaloric diet
75 management and are more expensive compared to ordin-
ary foods.32,33 In order to realize the benefits of phytosta-
nols, there is a need to devise a novel way of delivery.
Solid Lipid Nanoparticles (SLNPs), which were first
reported by Speiser and co-workers34 in 1986, are colloi-
80 dal delivery systems consisting of a lipid core and stabi-
lized by an outer shell made of an amphiphilic surfactant.
Their typical size may vary from 50 nm to 1 µm.35 As with
other nanoparticle-based systems, they have the potential
to improve hydrophobic molecule bioavailability.36,37
85 Furthermore, particles under 200 nm have been shown to
achieve longer circulation times in blood, compared with
larger particles regardless of their surface modifications,37
further improving their bioavailability.36,37 Reported man-
ufacturing processes for phytosterol nanocarriers involve
90the use of organic solvents such as hexane, isopropyl
alcohol, ethanol and acetone.38–40 However, there is con-
cern that the organic solvents may interact with the target
drug and cause toxicological and environmental
problems.41 An aqueous-based formulation©that avoids
95the use of organic solvents is desirable to improve safety,
as well as for environmental and economic impact.
Various studies demonstrate that the physical state and
structure of the carrier, formulation type, and particle
size of phytostanol formulation are important parameters
100that influence its cholesterol-lowering efficacy.42–48 Water-
soluble SLNPs have the potential to be novel and effective
delivery systems for phytostanols. The aim of this study
was to contribute to the better management of hypercho-
lesterolemia through the synthesis and characterization of
105SLNPs loaded with plant stanol ester (PSE).
Materials and Methods
Materials
Stearic acid (98%), palmitic acid (95%) and lecithin
(refined solid©) were purchased from Alfa Aesar
110(Haverhill, MA, US). Lauric acid (99.5+%) and sodium
taurocholate (98%) were procured from Sigma Aldrich (St
Louis, MO, US) and Acros Organics, Fisher Scientific
(Hampton, NH, US), respectively. Plant stanol ester
(91.2% sitostanol, 8.8% campestanol) was received as an
115in-kind donation from Raisio Nutrition Ltd. (Finland).
Double deionized water (18 MΩ·cm) purified by a purite
system was used throughout the experiments.
Anhydrous ethanol (99.9%) and n-heptane (99%) were
obtained from Fisher Scientific. Potassium hydroxide pellets
120(≥85%)©were purchased from Sigma Aldrich. Silylation
reagent, Bis (trimethylsilyl) trifluoroacetamide (BSTFA) +
1% Trimethylsilyl chloride (TMCS) (99%) was procured
from Supleco (Bellefonte, US). Pyridine (99+%) was bought
from Acros Organics (Geel, Belgium). Sitostanol standard
125(©>97%) was obtained from Matreya (Pennsylvania, US).
The growth medium used for cultivating HepG2 was
Dulbecco’s Modified Eagle’s Medium (DMEM) (1X) +
Glutamax (Gibco Life Technologies, Waltham, MA, US)
mixed with 10% fetal bovine serum (FBS, PAA
130Laboratories GmbH, Pasching, Austria), 1% Penicillin (100
units/mL) Streptomycin (100 µg/mL) (Sigma Aldrich) and
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1% Non-essential amino acids (Sigma Aldrich). DMEM
with L-glutamine (VWR International, Radnor, PA, US)
was used as the growth medium for HT-29 cells. The other
135 reagents used were sterile dimethyl sulfoxide (DMSO,
Fisher Scientific), 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-
phenyltetrazolium bromide (MTT reagent, Sigma Aldrich),
Phosphate Buffered Saline (PBS, Sigma Aldrich), Trypsin-
EDTA (VWR International), Trypan blue (Sigma Aldrich)
140 and Rhodamine 123 (Sigma Aldrich).
Methods
Formulation of Solid Lipid Nanoparticles
SLNPs were formulated by using biodegradable, biocompa-
tible lipids (stearic acid, palmitic acid, lauric acid) and
145 surfactants (lecithin and sodium taurocholate) by an aqu-
eous-based formulation process. PSE-free and PSE-loaded
SLNPs were prepared by the microemulsion method devel-
oped and optimised by Gasco’s group (Figure 1).49 The
composition of each formulation (Table 1) was varied in
150 order to evaluate the effect of different types of lipids used,
lecithin-to-sodium taurocholate ratio and stearic acid-to-
lecithin ratio. The melting points of lipids were determined
using a Stuart SMP10 melting point apparatus (Bibby
Scientific Limited, Stone, Staffordshire, UK). The melting
155 points of stearic acid, palmitic acid and lauric acid were
~©70°C, ~©63°C and ~©45°C, respectively, consistent with the
reported values.50–52 Lipids (450 mg) were melted by heat-
ing at approximately©10°C above their melting point. PSE
(75 mg) and lecithin were added to the molten lipid phase.
160 An aqueous solution of sodium taurocholate was heated to
the same temperature. The lipid phase and aqueous phase
were mixed together to yield a hot microemulsion under
magnetic stirring. The hot micro-emulsion was then
dispersed under magnetic stirring at 1000 rpm in cold
165water maintained between©2°C and 8°C for 30 minutes.
Analytical Method
Quantification of phytostanols was carried out on a high-
resolution gas chromatography (HRGC) MEGA 2 series
(Fisons Instruments, Manchester, UK) gas-liquid chromato-
170graph equipped with a flame ionization detector. The analy-
tical column was an HP-5, 5% phenyl methyl siloxane
stationary phase (30 m, 0.32 mm I.D., 0.25 µm). Gas chro-
matographic conditions were optimized as follows: detector
temperature,©300°C; injector temperature,©280°C; column
175temperature©250°C isothermal and injection volume, 1 µL.
Samples were injected under a 1:50 split mode using hydro-
gen as carrier gas (Claind Brezza, Lake Como, Italy) main-
tained at 6 bars with a run time of 20 minutes. A computer
chromatography data system (EZ Chrome 6.6
180Chromatography Data System, Scientific Software, Inc., San
Ramon, CA, US) was used to analyze the chromatograms.
Particle Size and ζ-Potential
Particle size and ζ-potential, which relates to surface
charge, were measured by tunable resistive pulse sensing
185(TRPS). This is a type of Coulter counter method that
employs a pore of tunable size immersed in a flow cham-
ber. The qNano instrument (Izon Science Ltd.,
Christchurch, New Zealand) was calibrated with monodis-
perse, carboxylated polystyrene particles (CPC200, nom-
190inal mean diameter of 210 nm and ζ-potential of −20 mV)
from Izon. The nanopore membranes (NP200, from Izon)
were specified for particles with diameters ranging from
©100 to 400 nm. The calibrant, as well as the samples, were
dispersed in PBS and subjected to a brief vortexing for
Figure 1 Formulation of solid lipid nanoparticles (SLNPs) by the microemulsion technique.AQ3
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195uniform mixing before measurements. The resistive cur-
rent pulse signals were analyzed using the Izon Control
Suite software 3.3.
Entrapment Efficiency and Drug Loading
A gas chromatography (GC) method was developed for
200the identification, separation, and quantification of phytos-
tanols. Methods used by the Food and Agricultural
Organization53 and Shapiro et al54 were followed to pre-
pare phytostanol samples for GC. The sample preparation
steps included saponification with ethanolic potassium
205hydroxide, liquid-liquid extraction with heptane, and deri-
vatization with BSTFA + 1% TMCS and pyridine. The
method was validated for linearity, selectivity, and speci-
ficity. Entrapment efficiency and drug loading were calcu-
lated by quantifying phytostanols in PSE SLNPs.
210A volume of PSE SLNPs equivalent to 7.5 mg of
phytostanol ester was subjected to centrifugation at 4400
g for 45 minutes. The resulting supernatant and pellet were
separated. The samples were saponified, extracted with
heptane and derivatized to determine the amounts of free
215PSE and PSE entrapped within the©lipid, respectively,
following the methods of Nandini et al55 and Tan et al.56
Entrapment efficiency (EE) and drug loading (DL) were
calculated according to equations 1 and 2 respectively.
Entrapment
efficiency %ð Þ ¼
Weight of entrapped drug
Weight of total drug
 100 (1)




Powder Flowability and Nanoparticle
220Yield
PSE free and PSE SLNP samples were©freeze-dried for
these tests. Samples with different lipids as carriers were
frozen at −©86°C (Forma Scientific, Inc., Marietta, Ohio,
US) overnight. The freeze-drying process was carried out
225at a condenser surface temperature of (−54 ± 3) °C at
a pressure of 19 Pa in a Heto PowerDry PL3000 freeze
dryer (Thermo Fisher Scientific, Waltham, US).
Powder flowability was evaluated using the angle of
repose method. The angle of repose is defined as the angle
230made by a material with respect to the horizontal when
piled.57 Approximately 1 gm of lyophilised PSE SLNPs
©was poured through a funnel onto a flat surface. The
funnel was positioned 2 cm from the horizontal surface,
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235 diameter (d) and height (h) of the pile were measured and
recorded. Equation 3 was used to calculate the angle of
repose (θ).
Angle of repose θð Þ¼ tan  1 h
0:5 d
(3)
©where d and h©are, respectively,© the diameter and
height of the pile.
240 The lyophilized SLNPs were used for spectroscopic
and thermal analysis, and stability studies. Nanoparticle
yield was calculated according to Nandini et al55 as the
weight of freeze-dried SLNPs in relation to the sum of the
starting material (equation 4).
Nanoparticle
yield %ð Þ ¼
Weight of nanoparticles
Weight of starting material
 100 (4)
245 One of the ten produced formulations of SLNPs was
selected based on desirable average particle diameter, ζ-
potential, maximum entrapment efficiency, maximum drug
loading, high nanoparticle yield and high quality of the
lyophilizate. The optimized formulation was further eval-
250 uated for particle size stability, shape and morphology,
spectroscopic properties, thermal behaviour, biological
safety, and cellular uptake.
Shape and Surface Morphology
Sample preparation involved depositing 10 µL of optimized
255 PSE SLNPs on a silicon wafer substrate. After drying for 24
hours at ambient temperature, images were collected. An
Asylum Research Cypher atomic force microscope (AFM,
Oxford Instruments, Santa Barbara, CA, US) in tapping
mode was used to record topographic and phase images of
260 SLNPs. AFM images were obtained by measurement of the
interaction forces between the silicon tip of a high resonant
frequency cantilever and the sample surface. The experi-
ments were performed in air at ambient temperature. The
topographical AFM images were processed by Proprietary
265 Scanning Probe Image Processor (SPIP) software version
6.64 (Image Metrology, Copenhagen, Denmark).
Spectroscopic Analysis
The Fourier transform infrared spectroscopy (FTIR) spec-
tra were obtained for PSE, stearic acid, physical mixture of
270 PSE and stearic acid, and lyophilized PSE SLNPs using
a Cary 630 FTIR spectrometer (Agilent Technologies Inc,
Santa Clara, CA, US). The samples were scanned at
a wavenumber ranging from©400 to 4000 cm
−1.
Thermal Analysis
275Differential scanning calorimetry (DSC) was performed
using model Q2000 equipped with an automated compu-
ter-controlled refrigerated cooling system (RSC-90) and
TZero pans (TA Instruments, New Castle, DE, US). The
weights of the sample were measured using a calibrated
280Sartorius CC6 balance. A predetermined weight of the
sample was placed in TZero alodine-coated aluminum
DSC pans and then hermetically sealed with a TZero
encapsulation press (TA Instruments, New Castle, DE,
US). An empty aluminium pan was used as the refer-
285ence. Phase transition temperatures and the melting point
of the samples were measured under a 50 mL per minute
dry ultra-high purity nitrogen gas (99.9998% purity)
purge. PSE, stearic acid, physical mixture of PSE and
stearic acid, lyophilized PSE free and PSE SLNPs were
290heated from©0°C to©330°C at the rate of©10°C per minute.
Triplicate melting scans were carried out to ensure melt-
ing point temperature reproducibility.
The heat stability of PSE, stearic acid, lyophilized PSE
free and PSE SLNPs was determined using a Q5000 ther-
295mogravimetric analysis (TGA) instrument (TA
Instruments, New Castle, US). Samples were heated in
a 100 µL platinum crucible from©25°C to©600°C at
a heating rate of©10°C per minute under a constant nitro-
gen flow of 25 mL per minute. The thermal decomposition
300profile of the samples was obtained. The weight loss data
for each sample were acquired in triplicate. The DSC and
TGA thermograms were analyzed using a TA universal
analysis software package.
Stability Studies
305The size distribution of PSE SLNPs was measured in
triplicate by particle tracking analysis (PTA) for the
assessment of stability. The measurements were taken
on day 1, day 7, day 15 and at monthly intervals up to 6
months. The average particle diameter was monitored at
310two different storage conditions, ie fridge and room tem-
perature protected from light. An LM10 Nanosight instru-
ment (Malvern Panalytical, Malvern, UK) equipped with
a 638 nm laser was used for the measurement of particle
size distribution. The lyophilizate was reconstituted in
315purified water in the amount of the original volume.
Samples were diluted in purified water and injected into
the sample chamber.©Three videos per sample of 60 sec-
onds duration were recorded. Data acquisition and proces-
sing were performed using NTA 2.3 analytical software.
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320 Cellular Studies
Human hepatocellular carcinoma, HepG2 and colon ade-
nocarcinoma, HT-29 cells were obtained from the
European Collection of Authenticated Cell Cultures
(ECACC). HepG2, derived from a fifteen-year-old
325 Caucasian male, express 3-hydroxy-3-methylglutaryl-
CoA reductase and hepatic triglyceride lipase activities.58
HT-29 was isolated from a primary tumour of a 44 years
old Caucasian female.59 Both the adherent cell lines were
cultured in a complete growth medium in a humidified
330 incubator (Heraeus Hera cell incubator, Thermo Electron
Corporation, Waltham, MA, US) of 5% CO2 in the air at
©37°C. For routine maintenance, the cell medium was
replaced every 48 hours. Cells were sub-cultured when
80% confluent by trypsinization with a 0.05% trypsin
335 and 0.02% ethylenediaminetetraacetic acid (EDTA) solu-
tion. All cell culture procedures were undertaken in
a BioMAT 2 microbiological safety cabinet (Thermo
Electron Corporation, Waltham, MA, US) using an aseptic
technique to ensure sterility.
340 Cytotoxicity Assay
Cells were seeded in a 96-well plate, at a density of 3×104
(HepG2) and of 4×104 (HT-29) cells per well in 100 µL
cell culture medium. Cells were allowed to equilibrate at
©37°C overnight to promote adhesion. At time zero, PSE
345 free and PSE SLNPs (0.5 mg mL−1) were added to each
replicate well and incubated for 24 hours. 20 µL of 3-(4,
5-dimethylthiazolyl-2)-2, 5-diphenyl-tetrazolium bromide
(MTT) (5 mg mL−1 in PBS) reagent was added to each
well and incubated at©37°C for 4 hours. The intracellular
350 formazan crystals were solubilized with dimethyl sulfox-
ide (200 µL per well). The plates were shaken for 15
minutes in R100 Rotatest Shaker (Luckham Ltd.,
Burgess hill, Sussex, England) in dark, and absorbance
values were measured using a FLUOstar Omega micro-
355 plate reader (BMG Labtech GmbH, Ortenberg, Germany).
Cell survival was expressed as a % absorbance at 570 nm
compared with control, ie untreated cells. HepG2 and HT-
29 treated with Triton X-100 were used as the negative
control, as the detergent action disrupts the cells. An
360 average of three separate experiments with three replicates
in each has been taken into consideration to determine
HepG2 and HT-29 survival after exposure to PSE free
and PSE SLNPs.
The cell survival of the samples was calculated using
365 equation 5.
Cell survival %ð Þ¼ Absorbance of treated cells




To evaluate whether the SLNPs could efficiently deliver
the drug into the cells, Rhodamine 123 (R123) was encap-
sulated into the SLNPs (F10) instead of PSE, as
370a fluorescent probe. The concentration of the dye with
respect to the lipid was 0.5%. The SLNPs so obtained
were sterilized by filtration through 0.2 µm filter units.
Particle Tracking Analysis (PTA) was used for the particle
sizing of PSE SLNPs (F10) and R123 SLNPs.
375HepG2 and HT-29 cells were cultured and seeded at
a density of 5.8 × 105 and 6 × 105 cells per©mL, respec-
tively, in a 12-well plate (COSTAR) for incubation over-
night. At time zero, cells were treated with R123 SLNPs
(100 μg per mL medium) and incubated for 2 hours at
380©37°C. HepG2 and HT-29 cells incubated with the medium
without the SLNPs served as controls. The cells were also
incubated with fluorescent SLNPs at©4°C to investigate the
role of endocytosis in SLNPs uptake. After incubation, cell
media was removed, and samples were washed with sterile
385PBS two times. Cells were examined using an inverted
fluorescence microscope (FM) (Olympus IX81, Olympus
Corporation, Tokyo, Japan) in order to visualize the fluor-
escence of the cargo fluorescent dye, Rhodamine 123.
After capturing images, uptake of R123 was assessed by
390flow cytometry. 300 µL of pre-warmed trypsin/EDTA was
added to each well to detach the adherent cells and incu-
bated for about 5 minutes. 700 µL of media was added to
each well to stop trypsinization. Cell solutions were cen-
trifuged (Eppendorf centrifuge 5702, Hamburg, Germany)
395at 125 g for 5 minutes. The cell pellets were washed with
ice-cold PBS twice and re-suspended in cold PBS. At least
ten thousand cells of each sample were analyzed using
a Guava Easycyte 8HT flow cytometer (FCM) (EMD
Millipore Corporation, Billerica, MA, US). Guava
400Express FCS4 express flow cytometry was used for data
analysis and for making overlay histograms.
Statistical Analysis
The data were presented as mean ± standard deviation
(SD). Quantitative data were analyzed by a one-way ana-
405lysis of variance (ANOVA) followed by Fisher’s least
significant difference test when significance was indicated.
p < 0.05 was considered statistically significant. Statistical
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Package for the Social Sciences (SPSS, version 25) was
used to analyze the data.
410 Results
Particle Size and ζ-Potential
PSE©-free and©PSE-loaded SLNPs employing three differ-
ent lipids (stearic acid, palmitic acid, lauric acid) and
varying concentration of surfactants were produced. The
415 particles appear spherical (see Figure S1
AQ4
of the supple-
mentary information) with an average particle diameter of
PSE SLNPs in the range of (171 ± 9) nm to (260 ± 20) nm
(Table 1). The type of lipid used to synthesize the SLNPs
had a significant impact on the resulting size of the parti-
420 cles. PSE SLNPs with stearic acid produced significantly
smaller nanoparticles than PSE SLNPs with palmitic acid.
SLNPs with lauric acid as the lipid produced significantly
larger nanoparticles compared to SLNPs with stearic acid.
Representative number-based size distributions of the
425 optimized formula of SLNPs, F9 and F10 are shown in
Figure 2. The D10, D50, D90 (particle size corresponding
to 10%, 50% and 90% of©the cumulative undersize parti-
cle size distribution, respectively) for F10 were (138 ± 8)
nm, (162 ± 8) nm, and (210 ± 8) nm, respectively, gen-
430 erating the lowest mean particle size of (171 ± 9) nm.
Increasing the concentration of lecithin and sodium taur-
ocholate in SLNPs had a significant effect on decreasing
their mean diameter. F6 had the highest PDI of 1.1 ± 0.4
whereas F2 had the lowest PDI of 0.22 ± 0.04 (Table 1).
435 The type of lipid used had a significant effect on the PDI,
with stearic acid producing the least polydisperse PSE
SLNPs.
A stability study was conducted for the optimized
formula of PSE SLNPs (F10) by measuring their average
440size by PTA over a period of 6 months. We evaluated two
different storage conditions and the results are shown in
Figure S2 of the supplementary information. The mean
diameter of F10 stored at©4°C was found to increase by
7.6% from (184 ± 6) nm after 6 months. On the other
445hand, when stored at room temperature, the same formula-
tion increased 20% in size over the same period.
ζ-potential values of SLNPs ranged from (−11 ± 5) mV
to (−28 ± 6) mV (Table 1). Lauric acid produced SLNPs
with a lower ζ-potential than stearic acid and palmitic acid.
450However, there were no differences in ζ-potential between
©drug-free and corresponding©drug-loaded SLNPs with
stearic acid and palmitic acid as the lipid, which appear
consistent with the drug being encapsulated inside the
particle carrier.
455Entrapment Efficiency and Drug Loading
The gas chromatograms in Figure 3 indicate that the
campestanol and sitostanol components (peaks 1 and©2,
respectively) could be separated under the GC condi-
tions. The retention time of the two compounds were
46010.2 and 12.9 minutes, respectively, and the peaks are
observed in both the sample containing the free phytos-
tanol components and that containing the phytostanol
loaded SLNPs. A calibration curve was plotted in the
concentration range from 0.2 µg/µL to 5.5 µg/µL with
465five concentration points. The response was linear with
a correlation coefficient (R2) of 0.995 (see Figure S3 of
the supplementary information). The maximum entrap-
ment efficiency and drug loading were found to be (89
± 5)% and (9.1 ± 0.5)©%, respectively, in F10, whereas
470F6 had the least amounts of drug entrapped at (74 ± 8)%
and loading of (7.1 ± 0.8)% (Table 1). The lipid matrix
used had a significant impact on the ability of SLNPs to
entrap and load PSE. F2, which contains stearic acid,
had a higher amount of PSE entrapped than F4 contain-
475ing palmitic acid and F6 containing lauric acid.
Likewise, SLNPs with stearic acid had higher drug
loading than palmitic acid. Compared to F2, the effect
of adding surfactants in F8 and F10 was not found to
entrap and load significantly higher amounts of the drug.
480There were no differences between palmitic acid (F4)
and lauric acid (F6) based SLNPs with regard to entrap-
ment efficiency.
Figure 2 Representative number-based particle size distribution of F9 (blue) and
F10 (red) solid lipid nanoparticles as measured by tunable resistive pulse sensing.
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Powder Flowability and Nanoparticle
Yield
485 The angle of repose of PSE SLNPs formulated with stearic
acid were 34 ± 2° (F2), 31 ± 1° (F8) and 33 ± 1° (F10).
The angle of repose of PSE SLNPs with palmitic acid as
the lipid matrix was 35 ± 3° (F4). However, SLNPs with
lauric acid (F6) as the lipid yielded a sticky lump of
490 powder. The nanoparticle yield ranged from (65 ± 8)% to
(68 ± 3)% (Table 1). The nanoparticle yield of F10 was
(67 ± 4)%.
F10 combined many positive critical quality attributes
such as desirable average particle diameter, ζ-potential,
495 maximum entrapment efficiency, maximum drug loading,
high nanoparticle yield and high quality of the lyophili-
zate. Hence, it was chosen as the optimized formulation
for stability assessment, shape and morphology studies,
spectroscopic analysis, thermal analysis, and in© vitro
500 studies.
Spectroscopic Analysis
The FTIR spectra of PSE, stearic acid, the physical mix-
ture of the drug with the lipid, and PSE SLNPs (F10) are
presented in Figure 4 and Table 2. FTIR spectra of PSE
505 revealed characteristic peaks at 2925 cm−1 and
2851 cm−1, both attributed to the -C-H groups.60 The
two sharp bands at 1737 cm−1 and 1179 cm−1 represent
absorption of the carbonyl group from the ester
component.60,61 The spectra for stearic acid showed
510absorption bands with characteristic peaks at 2914 cm−1,
2847 cm−1 and 1700 cm−1, corresponding to –C-H,
-C-H and C=0 groups, respectively.60 The prominent
peaks of the drug and stearic acid were all present in the
physical mixture. The FTIR spectrum of PSE SLNPs
515shows approximately all absorbance of the lipid matrix.
However, the peaks corresponding to the carbonyl group
of the plant stanol ester©were absent. There were no major
shifts of peak or new bands in the lyophilized©PSE-loaded
SLNPs.
520Thermal Analysis
Figure 5A shows the DSC curves of PSE, stearic acid,
lyophilized PSE free and PSE SLNPs. PSE exhibits
a melting range between 25.7 °C and 41.1 °C with the
melting peak at 34.5 °C. Stearic acid melts between 62.0 °
525C and 81.5 °C with the melting point at 71.5 °C. There
was no significant shift in the position of the endothermic
peak in the melting range of stearic acid in the optimized
PSE SLNPs. After formulation into SLNPs, the peak of
PSE disappeared, and the only peak observed was of the
530lipid, stearic acid.
The thermal degradation profiles of PSE, SA, PSE free
and PSE SLNPs are depicted in Figure 5B. PSE presented
a thermal event at©306.6°C, which was followed by 97.2%
degradation when heated to©420°C. The TGA curve of
535stearic acid showed thermal decomposition of approxi-
mately 95% when heated from©190.4°C to©288°C followed
by elimination of carbonaceous material. PSE SLNPs
showed thermal decomposition at temperatures above
©130°C. All the tested samples degraded to a minimal
540amount of residue when heated to©600°C.
Cytotoxicity Assay
The results of the MTT assay are shown in Figure 6. When
HepG2 cells were incubated with PSE free and PSE
SLNPs for 24 hours, cell survival was (99 ± 4)% and (98
545±8) % compared with untreated controls, respectively.
Likewise, the percentage survival of HT-29 after exposure
to PSE free and PSE SLNPs overnight©were (97 ± 2)% and
(97 ± 6)%, respectively. There were no significant differ-
ences in cell survival between untreated cells and cells
550incubated with©drug-free or drug-loaded SLNPs.
Cellular Uptake
The PTA mean diameters of PSE SLNPs (F10) and R123
SLNPs were (183 ± 5) nm and (187 ± 4) nm, respectively.
Figure 3 Gas chromatogram of phytostanol (A), phytostanol free SLNPs (B),
phytostanol loaded SLNPs (C).
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Figure 4 Fourier-transform infrared spectroscopy (FTIR) spectra for plant stanol ester (A), stearic acid (B), plant stanol ester + stearic acid (C) and plant stanol ester solid
lipid nanoparticles (D).
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A strong green fluorescence signal was observed with liver
555 and intestinal cells treated with Rhodamine 123 SLNPs at
37° C (see Figure S4 of the supplementary information).
The untreated cells and the cells incubated with
Rhodamine 123 free SLNPs did not exhibit fluorescence.
The cells treated with free dye and incubated at 4° C with
560 R123 SLNPs exhibited very negligible fluorescence.
A significant shift in mean fluorescence intensity was
observed in HepG2 and HT-29 treated with R123 SLNPs
incubated at 37°C, using flow cytometry (Figure 7).
Discussion
565 SLNPs represent an advancement of drug delivery systems
such as emulsions, liposomes, microparticles and polymer-
based nanoparticles.62 The rationale for choosing SLNPs
as a vehicle for delivery of plant esters, such as their small
size, stability, high drug entrapment, safety and effective-
570 ness as drug carriers,©was demonstrated. Hence, PSE
SLNPs are potentially suitable for oral administration to
lower LDL-C and manage hypercholesterolaemia. The
intended delivery form of PSE SLNPs is as a dry powder
packaged in sachets which can be sprinkled on food, as
575and when necessary, giving patients the flexibility to con-
sume it with any meal during the day. The use of PSE
SLNPs sachets is appealing and convenient since it is
easier to incorporate these into a lipid-lowering regimen
compared with dietary adjustments necessary to include
580food products.
SLNPs were manufactured by a simple and solvent-
free microemulsion method. This technique is highly
attractive for scale-up to industrial production due to
the green chemistry and the low mechanical energy
585input, through magnetic stirring, needed to form nano-
sized SLNPs. In contrast, the homogenization methods
used for SLNP formulation are energy-intensive and may
cause thermodynamic and mechanic stress to the
product.41,63 Furthermore, commonly used solvent emul-
590sification-evaporation, emulsification solvent diffusion
Table 2 FTIR Interpretation of Plant Stanol Ester, Stearic Acid, Physical Mixture and PSE SLNPs
Ingredients Wave Number (cm−1) and Corresponding Functional Groups
Plant stanol ester (PSE) 2925 2851 1737 1179
-C-H -C-H RCOO C-O-C
Stearic acid (SA) 2914 2847 1700 1473
-C-H -C-H C=O –CH2- or –CH3
PSE + SA 2918, 2851 1737 1704 1182
-C-H RCOO C=O C-O-C
Plant stanol ester solid lipid nanoparticles (PSE SLNPs) 2918 2851 1704 1473
-C-H -C-H C=O –CH2- or –CH3
Figure 5 (A) Differential scanning calorimetry (DSC) thermograms of plant stanol ester (PSE), stearic acid, PSE + stearic acid, lyophilized©PSE-free solid lipid nanoparticles
(SLNPs) and PSE SLNPs. (B) Thermogravimetric Analysis (TGA) curve of PSE, stearic acid, lyophilized©PSE-free SLNPs and PSE. SLNPs.
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and solvent-injection methods employ organic solvents.64
Solvent removal may be incomplete and costly, the resi-
dues may cause adverse effects and interaction with the
drug may lead to stability issues.41 Thus, the aqueous-
595 based microemulsion technique employed is favourable
compared with solvent-based methods taking into
account toxicological, environmental and regulatory
concerns.
The SLNPs formulated had a favourable mean dia-
600 meter (<260 nm) within the range of diameters of most
clinically approved nanoparticles, from©50 to 300 nm.
65
However, nanoparticles of 200 nm diameter or larger tend
to activate the complement system and are removed from
the circulation faster compared to nanoparticles less than
605 200 nm.66 Nano-sized PSE SLNPs (F10) with an average
diameter (171 ± 9) nm may have a greater ability to
compete with cholesterol for access to its receptors, and
to be incorporated into mixed micelles, and therefore have
greater©cholesterol-lowering efficacy due to the increment
610 in surface area.
The most widely used nanocarriers for delivering drugs
to combat atherosclerosis have been lipid-based.67 Stearic
acid (C18), palmitic acid (C16) and lauric acid (C12) were
chosen based on their “generally regarded as safe”
615(GRAS) categorization by the Food and Drug
Administration,68 high melting point and their increasing
use as drug carriers.49 SLNPs formulated with the longest
chain lipid, stearic acid, had the lowest average diameter,
were less polydisperse, were stable, and entrapped the
620highest amounts of PSE. On the other hand, SLNPs fabri-
cated with the shortest chain fatty acid, lauric acid, had the
largest diameter, were highly disperse, the least stable and
incorporated the least amounts of the drug. The observed
inverse relation of fatty acid carbon chain length to the
625average diameter of SLNPs agrees with the findings of
Holt et al.69 Particle samples with PDI values below 0.3
are considered to have a narrow size distribution, with PDI
below 0.1 being referred to as monodispersed.70
According to this, most SLNPs synthesized in this work
630have a broad size distribution. Tails of the distribution at
higher size values for SLNPs may be due to some level of
aggregation. A key benefit©of stearic acid is that, unlike
palmitic acid and lauric acid, it does not appear to increase
LDL-C in vivo.71,72 In fact, it is converted to
635a monounsaturated fatty acid, oleic acid which lowers
LDL-C and triglyceride levels.73–75 Hence, the formula-
tion combines the natural cholesterol-lowering properties
of PSE and stearic acid.76 Stearic acid was also the best for
the incorporation of lipophilic PSE as it had higher entrap-
640ments, 82–89% and drug loading, 8.3–9.1% compared
with palmitic acid (©76% and 7.6%, respectively) and lauric
acid (©74% and 7.1%, respectively). SLNPs have been
found to entrap lipophilic and hydrophilic drugs to varying
Figure 7 Flow cytometry data of HepG2 (A) and HT-29 (B) showing the mean fluorescence intensity of untreated cells (black) and the uptake of fluorescent solid lipid
nanoparticles (SLNPs) by cells at 37 °C (green).
Figure 6 HepG2 and HT-29 survival after exposure to plant stanol ester (PSE) free
and PSE solid lipid nanoparticles (SLNPs) overnight, *p > 0.05, **p < 0.05.
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degrees. Entrapment efficiencies around 50–70% for
645 carbamazepine,77 90% for atorvastatin,78 95% for
simvastatin79 and 50% for rosuvastatin80 have been
reported. The high molecular weight, melting point, and
hydrophobicity due to stearic acid being a long-chain fatty
acid may account for a higher incorporation of the drug in
650 the lipid matrix during formulation, compared with the
shorter fatty acids. The amount of drug within the lipid
matrix co-relates with the functionality and ultimately the
bioavailability from the drug delivery system.56 The high
values of EE and DL demonstrate the efficiency and cost-
655 effectiveness of this method for the preparation of PSE
SLNPs.
The SLNPs were prepared using two physiological
surfactants, lecithin and sodium taurocholate to stabilize
the formulations. These are preferable to surfactants com-
660 monly used for SLNP fabrication such as butanol©and iso-
propanol©with respect to safety and regulatory aspects.
81,83
A 2:1 ratio of lecithin to sodium taurocholate produced
SLNPs with a mean diameter (213 ± 4) nm, whereas an
equal ratio produced smaller nanoparticles. This is likely
665 due to the fact that the increased concentration of surfac-
tant reduces the interfacial tension between the lipid
matrix and dispersion medium. Increasing the amounts of
surfactants did not significantly increase the amount of
PSE entrapped within the stearic acid matrix. This indi-
670 cates that the optimized PSE SLNPs (F10) had an opti-
mum level of surfactants in the external phase. The
concentration of lecithin and sodium taurocholate were
adequate to stabilize and cover the surface of the nanofor-
mulations effectively.
675 The ζ-potential values indicate that the formulations
are electrostatically stable, ie approximately −25 mV.72,82
The surface chemistry critically affects the way nanopar-
ticles interact with each other and with their surrounding
environment.83 The consistently negative ζ-potential
680 values explain the stability by maintaining electrostatic
repulsion among the particles. Stearic acid has a pKa
value of 4.7550 and in the conditions that the SLNPs
have been synthesized (pH approximately 5.8), it is nega-
tively charged. A net negative charge of lecithin84 and the
685 anionic nature of sodium taurocholate85 could have further
contributed to the negative surface charge and electrostatic
stabilisation of the SLNPs. The surface charge values of
PSE free and PSE SLNPs with stearic acid and palmitic
acid as the lipid matrix are comparable. This seems to
690 indicate that all the nanoformulations, apart from F6,
have the drug entrapped within the lipid and not deposited
on the surface.
Aqueous dispersions of PSE SLNPs were freeze-dried
to preserve the nano-size range, particle properties and
695improve the stability of the SLNPs. An angle of repose
less than 30° indicates excellent flowability and angles
between©31° and 35° denote good flowability.
55 Hence,
lyophilisation was found to be successful in preparing
free-flowing discrete SLNPs formulated with stearic acid
700(F2, F8, F10) and palmitic acid (F4). The lyophilized
SLNPs showed 0.5% moisture loss below 100°C, indicat-
ing that effective lyophilization of the SLNPs is possible,
since moisture content was less than the 5% acceptable in
the pharmaceutical industry.86 The free-flowing dry pow-
705der formed by lyophilization of the optimized PSE SLNPs
presents exciting opportunities for handling, reconstitu-
tion, and compressibility of the powder into other oral
dosage forms.
TGA demonstrates that the optimized PSE SLNPs are
710thermally stable until approximately©130°C. The physical
state of plant stanols has implications for their efficacy.43
The microcrystalline structure of sitostanol was postulated
to impair its dissolution in the small intestine46 and crys-
talline phytosterols were not absorbed efficiently in the
715intestine resulting in low bioaccessibility.39 The disappear-
ance of the melting endotherm in DSC and absorption
bands in FTIR, after entrapment in the lipid matrix, indi-
cates the amorphous state of the drug in the optimized
SLNPs. The amorphous form of PSE can be expected to
720have better drug dispersion and enhanced drug-matrix
association suitable for controlled release compared to
crystalline forms.86 The presence of surfactants might
have prevented the crystallization of PSE dispersed within
the lipid.
725A prolonged shelf life of the formulation is indicated
by the lack of change of the particle size of lyophilized
PSE SLNPs when stored at©4°C over a period of 6 months.
The formulations were less stable at room temperature, at
which a gradual increase in particle size was observed
730starting at 90 days, presumably due to the increased kinetic
energy of SLNPs at higher temperatures.87
The in©vitro assessment of optimized PSE SLNPs was
conducted on HT-29 and HepG2 cell culture models of
intestinal and hepatic cells, respectively, since phytosta-
735nols lower LDL-C by inhibiting intestinal and hepatic
cholesterol absorption.88–90 According to the
International Standards Organization (ISO) 10993–5,
a reduction of cell viability by more than 30% is
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considered cytotoxic.91 The concentration of phytostanol
740 used in MTT assay (65 μM) was much higher than normal
serum physiological concentration (0.6 μM) and after diet-
ary supplementation (1.2 μM) on cultured human blood
cells.92 Therefore, the MTT assay indicates that the opti-
mized PSE SLNPs are not cytotoxic,93 and are likely not
745 toxic in vivo.
Rhodamine 123 was chosen as a fluorescent probe
since it is lipophilic and has a molecular weight (380.8
g/mol)94 similar to stanols (sitostanol: 416.7 g/mol, cam-
pestanol: 402.6 g/mol).95,96 The entrapment of the dye did
750 not have any significant influence on the characteristics of
the SLNPs since the average diameter of R123 SLNPs©was
comparable to PSE SLNPs. A strong green fluorescence
signal of R123 SLNPs within the hepatic and intestinal
cells©visualised by fluorescence microscopy and significant
755 shift in mean fluorescence intensity by flow cytometry
compared to untreated cells demonstrated efficient uptake
of fluorescent SLNPs. There was no significant uptake of
R123 SLNPs when incubated with cells at 4°C, suggesting
a mechanism of uptake involving endocytosis. Negligible
760 fluorescence of cells treated with R123 free SLNPs, free
dye,©indicates that Rhodamine 123, by itself, was not
internalized. This demonstrated the suitability of SLNPs
as novel and effective drug carriers for therapeutic appli-
cations. SLNPs with a mean diameter of 80–300 nm have
765 been reported to be taken up by different cell lines through
various endocytic pathways.97 Martins and colleagues
reported similar findings for Rhodamine 123-loaded
SLNPs having a mean size 135–175 nm and −20 mV
surface charge.98 Likewise, Rhodamine 123-loaded
770 SLNPs (average diameter 224 nm) were taken up by
multidrug-resistant breast cancer cells by endocytosis.99
The nano-scaled size, generally spherical shape and nega-
tive surface charge might have contributed to the interna-
lization of SLNPs.100
775 The methodology of SLNP formulation described may
also have application for other poorly soluble active com-
pounds for drug delivery applications.
Conclusion
A novel aqueous-based formulation incorporating plant sta-
780 nol ester within SLNPs as the carrier has been successfully
devised, characterized, and optimized. The method is sim-
ple, energy-efficient and has excellent scale-up potential.
The synthesis is based on green technology since organic
solvents were not used and little waste has been generated.
785 The optimal nano-sized formulation of PSE SLNPs has
a spherical shape and a negative surface charge that stabi-
lizes them. Approximately 89% of the drug was entrapped
within the carrier in an amorphous form with drug excipient
compatibility and the formulation has been found to be
790stable for at least six (6) months. The optimized PSE
SLNPs are not toxic to hepatic and intestinal cell lines and
are rapidly taken up by the cells within two (2) hours.
The formulation has the potential to be used as
a therapeutic dietary supplement of cholesterol-lowering
795drugs leading to the administration of lower doses of drugs
and reducing the incidence of adverse drug reactions. The
formulation may have the potential to avoid the need for
drug therapy altogether. This work offers an alternative
approach in the clinical management of patients with
800hypercholesterolemia that could contribute to better ther-
apeutic outcomes of cardiovascular diseases.
Future Work
The absorption of SLNPs across the intestinal barrier can
be studied in vitro using cell culture models of intestinal
805epithelial cells in a trans-well arrangement to monitor
movement from apical to basal compartments through
the epithelial cell barrier. The efficacy of PSE SLNPs as
a©cholesterol-lowering agent in vivo needs to be demon-
strated in animal models, coupled with an assessment of
810the uptake and pharmacokinetics of the SLNPs in the
circulation. Further in vitro work could focus on the
potential interaction of the SNLPs with the low density-
lipoprotein receptor and LDL-C, to establish how choles-
terol metabolism is affected.
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